JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
Description: Zileuton (also known as A-64077; Abbott 64077; ZYFLO; ZYFLO CR) is a novel, potent and orally bioactive inhibitor of 5-lipoxygenase, and thus inhibits leukotrienes (LTB4, LTC4, LTD4, and LTE4) formation, it was introduced in 1996 to decrease the symptoms of asthma. Zileuton suppresses PG biosynthesis by interference with arachidonic acid (AA) release in macrophages. Zileuton significantly reduces PGE2 and 6-keto prostaglandin F1alpha (PGF1alpha) levels in activated mouse peritoneal macrophages and in J774 macrophages. Zileuton inhibits PGE2 production in LPS-stimulated human whole blood and suppresses PGE2 and 6-keto PGF1alpha pleural levels in rat carrageenan-induced pleurisy.
References: Br J Pharmacol. 2010 Oct; 161(3):555-70; Gut. 1996 Jun; 38(6):899-904; Br J Pharmacol. 2008 Feb; 153(3):568-82.
Related CAS#: 118569-21-4 (Zileuton sodium); 111406-87-2 (free)
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.
Request Data Sheet
Request product datasheet
Request safety datasheet
Compare
Add to wishlist
Get an offer
Request delivery time
Ask a technical question
Submit a bulk request
sales@hoelzel.de
« Back
Subscribe, get 15% off every fifth order and have your items delivered on time!
Forgot Your Password?
Not yet registered? Create account here!